이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients

2015년 11월 6일 업데이트: Astellas Pharma Inc

A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients

A study to assess the safety and efficacy of Alefacept in de novo kidney transplant patients.

연구 개요

상세 설명

This is a 4 arm (all active) study to determine the safety and efficacy of Alefacept in de novo kidney transplant recipients.

연구 유형

중재적

등록 (실제)

323

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • California
      • Loma Linda, California, 미국, 92354
        • Loma Linda University Medical Center
      • Los Angeles, California, 미국, 90033
        • University of Southern California - University Hospital
      • Los Angeles, California, 미국, 90057
        • St. Vincent/National Institute of Transplantation
      • Sacramento, California, 미국, 95817
        • UC Davis Medical Center
      • San Diego, California, 미국, 92103
        • UCSD
      • San Diego, California, 미국, 92123
        • California Institute of Renal Research/Sharp Memorial Hospital
      • San Francisco, California, 미국, 94143
        • University of California - San Francisco
    • Colorado
      • Aurora, Colorado, 미국, 80045
        • University of Colorado Health Science Center
    • Florida
      • Gainesville, Florida, 미국, 32610
        • University of Florida, Shands Hospital, Gainesville
      • Jacksonville, Florida, 미국, 32224
        • Mayo Clinic - Jacksonville
    • Georgia
      • Augusta, Georgia, 미국, 30921
        • Medical College of Georgia, Augusta
    • Illinois
      • Chicago, Illinois, 미국, 60612
        • University of Illinois at Chicago
      • Chicago, Illinois, 미국, 60637
        • University Of Chicago Medical Center
      • Chicago, Illinois, 미국, 60612
        • Rush - Presbyterian - St. Lukes Medical Center
    • Kentucky
      • Lexington, Kentucky, 미국, 40536
        • University of Kentucky
    • Maryland
      • Baltimore, Maryland, 미국, 21201
        • University of Maryland Center
    • Massachusetts
      • Boston, Massachusetts, 미국, 02115
        • Brigham and Women's Hospital
      • Boston, Massachusetts, 미국, 02111
        • Tufts Medical Center
    • Michigan
      • Ann Arbor, Michigan, 미국, 48109
        • University of Michigan
    • New Jersey
      • Livingston, New Jersey, 미국, 07039
        • St. Barnabas Medical Center
    • New York
      • Buffalo, New York, 미국, 14203
        • Buffalo General Hospital
      • New York, New York, 미국, 10029
        • Mt. Sinai School of Medicine
      • New York, New York, 미국, 10065
        • New York Presbyterian Hospital - Cornell
      • Valhalla, New York, 미국, 10595
        • Westchester Medical Center
    • North Carolina
      • Chapel Hill, North Carolina, 미국, 27599
        • University of North Carolina
      • Durham, North Carolina, 미국, 27710
        • Duke University Medical Center
    • Ohio
      • Cleveland, Ohio, 미국, 44106
        • University Hospital of Cleveland
    • Oregon
      • Portland, Oregon, 미국, 97239
        • Oregon Health & Science University
      • Portland, Oregon, 미국, 97210
        • Legacy Transplant Services
    • Pennsylvania
      • Harrisburg, Pennsylvania, 미국, 17101
        • Pinnacle Health at Harrisburg
      • Philadelphia, Pennsylvania, 미국, 19104
        • University of Pennsylvania
    • Tennessee
      • Memphis, Tennessee, 미국, 38104
        • Methodist University Hospital - Memphis
    • Texas
      • Dallas, Texas, 미국, 75246
        • Baylor University Medical Center
      • Houston, Texas, 미국, 77030
        • Methodist Hospital Research Institute of Houston
    • Utah
      • Salt Lake City, Utah, 미국, 84132
        • University of Utah Medical Center
    • Virginia
      • Richmond, Virginia, 미국, 23298
        • Virginia Commonwealth University School of Medicine
    • Washington
      • Seattle, Washington, 미국, 98195
        • University of Washington Medical Center
    • Wisconsin
      • Madison, Wisconsin, 미국, 53792
        • University of Wisconsin Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Subject is anticipated to receive first oral dose of tacrolimus within 48 hours of transplant procedure
  • Subject is a recipient of a de novo kidney transplant
  • Subject is a recipient of a kidney from a non-human leukocyte antigen (HLA) identical related living donor, a non-related living donor, or a deceased donor

Exclusion Criteria:

  • Subject has a screening (pre-operative)estimated cluster of differentiation (CD) 4+ T-cell count of < 250 cells/µL
  • Subject will receive a kidney with an anticipated cold ischemia time (CIT) of > 30 hours
  • Recipient has a positive T or B-cell cross match by investigational site's standard method of determination
  • Subject will receive a kidney from a 50-65 year old deceased donor with one of the following:

    • History of hypertension and a terminal serum creatinine > 1.5 mg/dL
    • Cerebrovascular accident as cause of death and a terminal serum creatinine > 1.5 mg/dL
    • History of hypertension and cerebrovascular accident as cause of death and a terminal serum creatinine > 1.5 mg/dL

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Tacrolimus/MMF/Basiliximab
Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.
The initial dose of tacrolimus was administered orally within 48 hours post-transplant. Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.
다른 이름들:
  • 프로그래프, FK506
Administered as a 20 mg bolus injection within 2 hours prior to transplantation and a 20 mg bolus injection on Day 3.
다른 이름들:
  • 시뮬렉트
Administered at 750 mg twice per day orally or intravenously for patients enrolled under Amendment 6 or earlier and at 1000 mg twice per day orally or intravenously for patients enrolled under Amendment 7. The dose of MMF could be adjusted based on clinical symptoms.
다른 이름들:
  • 셀셉트, MMF
Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
실험적: Alefacept QW/Tacrolimus/MMF
Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.
The initial dose of tacrolimus was administered orally within 48 hours post-transplant. Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.
다른 이름들:
  • 프로그래프, FK506
Administered at 750 mg twice per day orally or intravenously for patients enrolled under Amendment 6 or earlier and at 1000 mg twice per day orally or intravenously for patients enrolled under Amendment 7. The dose of MMF could be adjusted based on clinical symptoms.
다른 이름들:
  • 셀셉트, MMF
Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
Administered as a 7.5 mg intravenous bolus on day 0 (intraoperatively, prior to kidney revascularization) and Day 3; subsequently administered subcutaneously either weekly or every 2 weeks.
다른 이름들:
  • 아메비브, ASP0485
실험적: Alefacept QW/Tacrolimus
Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.
The initial dose of tacrolimus was administered orally within 48 hours post-transplant. Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.
다른 이름들:
  • 프로그래프, FK506
Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
Administered as a 7.5 mg intravenous bolus on day 0 (intraoperatively, prior to kidney revascularization) and Day 3; subsequently administered subcutaneously either weekly or every 2 weeks.
다른 이름들:
  • 아메비브, ASP0485
실험적: Alefacept QOW/Tacrolimus/MMF
Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.
The initial dose of tacrolimus was administered orally within 48 hours post-transplant. Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.
다른 이름들:
  • 프로그래프, FK506
Administered at 750 mg twice per day orally or intravenously for patients enrolled under Amendment 6 or earlier and at 1000 mg twice per day orally or intravenously for patients enrolled under Amendment 7. The dose of MMF could be adjusted based on clinical symptoms.
다른 이름들:
  • 셀셉트, MMF
Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
Administered as a 7.5 mg intravenous bolus on day 0 (intraoperatively, prior to kidney revascularization) and Day 3; subsequently administered subcutaneously either weekly or every 2 weeks.
다른 이름들:
  • 아메비브, ASP0485

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Percentage of Participants With Biopsy-confirmed Acute Rejection (BCAR) at Month 6 Assessed by Local Review
기간: 6 months

Rejection episodes were confirmed by biopsy by the clinical site pathologist. Biopsies were graded according to the 2005 Banff criteria. All biopsies (T-cell and/or antibody mediated) of grade 1 or higher were considered a BCAR.

The Kaplan-Meier estimates at Day 182 was used for the analyses at 6 months. Lost to follow-up or patients with missing outcomes were censored at their last follow up visit.

6 months

2차 결과 측정

결과 측정
측정값 설명
기간
Patient Survival at Month 6 and Month 12
기간: 6 months and 12 months

Patient survival is any participant who is known to be alive 6 months and 12 months after the skin closure date.

The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.

6 months and 12 months
Graft Survival at Month 6 and Month 12
기간: 6 months and 12 months

Graft survival was defined as any participant who was known to have a functioning graft (i.e., not graft loss) at 6 months and 12 months after the skin closure date. Graft loss was defined as patient death, retransplant, permanent return to dialysis (dialysis greater than 30 days) or transplant nephrectomy.

The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.

6 months and 12 months
Percentage of Participants With BCAR at Month 12 Assessed by Local Review
기간: 12 months

Rejection episodes were confirmed by biopsy by the clinical site pathologist. Biopsies were graded according to the 2005 Banff criteria. All biopsies (T-cell and/or antibody mediated) of grade 1 or higher were considered a BCAR.

The Kaplan-Meier estimates at Day 365 was used for the analyses at 12 months. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.

12 months
Percentage of Participants With BCAR at Month 6 and 12 Assessed by Central Review
기간: 6 months and 12 months

Rejection episodes were confirmed by biopsy by a central reviewer. Biopsies were graded according to the 2005 Banff criteria. All biopsies (T-cell and/or antibody mediated) of grade 1 or higher were considered a BCAR.

The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.

6 months and 12 months
Percentage of Participants With T-cell Mediated BCAR at Month 6 and 12 Assessed by Local Review
기간: 6 months and 12 months

Rejection episodes were confirmed by biopsy by the clinical site pathologist. Biopsies were graded according to the 2005 Banff criteria. All biopsies of grade 1 or higher were considered a BCAR.

The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.

6 months and 12 months
Percentage of Participants With T-cell Mediated BCAR at Month 6 and 12 Assessed by Central Review
기간: 6 months and 12 months

Rejection episodes were confirmed by biopsy by the central reviewer. Biopsies were graded according to the 2005 Banff criteria. All biopsies of grade 1 or higher were considered a BCAR.

The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.

6 months and 12 months
Change From Week 4 in Glomerular Filtration Rate Estimated by the MDRD Method at Month 6 and Month 12
기간: Week 4, Month 6 and Month 12
The glomerular filtration rate (GFR) was calculated using the Modification of Diet in Renal Disease (MDRD) method.
Week 4, Month 6 and Month 12
Change From Week 4 in GFR by Iothalamate Clearance at Month 6
기간: Week 4 and Month 6
The glomerular filtration rate was measured directly using iothalamate clearance.
Week 4 and Month 6
Change From Week 4 in Serum Creatinine at Month 6 and 12
기간: Week 4 and Month 6 and 12
Week 4 and Month 6 and 12
Percentage of Participants With Efficacy Failure at 6 and 12 Months Assessed by Local Review
기간: 6 months and 12 months
Efficacy failure is defined as death, graft failure (permanent return to dialysis [>30 days] or retransplant), BCAR according to local review, or lost to follow-up.
6 months and 12 months
Percentage of Participants With Efficacy Failure at 6 and 12 Months Assessed by Central Review
기간: 6 months and 12 months
Efficacy failure is defined as death, graft failure (permanent return to dialysis [>30 days] or retransplant), BCAR according to central review, or lost to follow-up.
6 months and 12 months
Time to First BCAR Assessed by Local Review
기간: 12 months
The time to first BCAR (local review) was calculated as the first biopsy date in which the local reviewer confirmed an acute rejection minus the date of skin closure +1. Only participants with a BCAR are included in the analysis.
12 months
Time to First BCAR Assessed by Central Review
기간: 12 months
The time to first BCAR (central review) was calculated as the first biopsy date in which the central reviewer confirmed an acute rejection minus the date of skin closure +1. Only participants with a BCAR are included in the analysis.
12 months
Time to First T-cell Mediated BCAR Assessed by Local Review
기간: 12 months
The time to first T-cell mediated BCAR (local review) was calculated as the first biopsy date in which the local reviewer confirmed an acute rejection minus the date of skin closure +1.
12 months
Time to First T-cell Mediated BCAR Assessed by Central Review
기간: 12 months
The time to first T-cell mediated BCAR (central review) was calculated as the first biopsy date in which the central reviewer confirmed an acute rejection minus the date of skin closure +1. Only participants with a T-cell mediated BCAR are included in the analysis.
12 months
Maximum Grade of T-cell Mediated Rejection Assessed by Local Review
기간: 6 months and 12 months

The grade of acute T-cell mediated rejection was classified as IA, IB, IIA, IIB and III according to Banff 2005 criteria. If a patient had more than 1 T-cell mediated rejection, the episode with the most severe grade was used in the analysis.

Grade IA: Cases with significant interstitial infiltration (> 25% of parenchyma affected) and foci of moderate tubulitis; Grade IB: Cases with significant interstitial infiltration (> 25% of parenchyma affected) and foci of severe tubulitis; Grade IIA: Cases with mild to moderate intimal arteritis; Grade IIB: Cases with severe intimal arteritis comprising >25% of the luminal area; Grade III: Cases with "transmural" arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation.

6 months and 12 months
Maximum Grade of T-cell Mediated Rejection as Assessed by Central Review
기간: 6 months and 12 months

The grade of acute T-cell mediated rejection was classified as IA, IB, IIA, IIB and III according to Banff 2005 criteria. If a patient had more than 1 T-cell mediated rejection, the episode with the most severe grade was used in the analysis.

Grade IA: Cases with significant interstitial infiltration (> 25% of parenchyma affected) and foci of moderate tubulitis; Grade IB: Cases with significant interstitial infiltration (> 25% of parenchyma affected) and foci of severe tubulitis; Grade IIA: Cases with mild to moderate intimal arteritis; Grade IIB: Cases with severe intimal arteritis comprising >25% of the luminal area; Grade III: Cases with "transmural" arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation.

6 months and 12 months
Percentage of Participants With Clinically Treated Acute Rejection at Month 6 and Month 12
기간: 6 months and 12 months
Patients who received immunosuppressive medications for the treatment of suspected or BCAR were considered to have a clinically-treated acute rejection.
6 months and 12 months
Percentage of Participants With Anti-lymphocyte-treated Rejection at Months 6 and 12
기간: 6 months and 12 months

Participants with histologically proved Banff Grade II or III rejection could receive anti-rejection therapy with anti-lymphocyte antibodies per institutional protocol.

The use of anti-lymphocyte antibody therapy at any time during a suspected or proven rejection episode for the treatment of acute rejection was considered an event.

6 months and 12 months
Percentage of Participants With Multiple Rejection Episodes at Months 6 and 12
기간: 6 months and 12 months
All participants were evaluated for the incidence of multiple rejection episodes (clinically treated and/or BCAR as assessed by the local reviewer) through 6 months and 12 months.
6 months and 12 months
Percentage of Participants With Treatment Failure at Month 6 and 12
기간: 6 months and 12 months
Treatment failure was defined as death, graft loss, BCAR (local review), lost to follow-up or early discontinuation of treatment regimen. The Kaplan-Meier estimates at Days 182 and 365 were used for the analyses at 6 months and 12 months respectively. Lost to follow-up or participants with missing outcomes were censored at their last follow up visit.
6 months and 12 months
Gastrointestinal Quality of Life Index Score Over Time
기간: Months 1, 3, 6, and 12
The impact of gastrointestinal (GI) symptoms on health-related quality of life was assessed using the Gastrointestinal Quality of Life Index (GIQLI) symptom severity score. The GIQLI is a 36-item self-administered questionnaire that assesses the impact of gastrointestinal symptoms during the past 2 weeks on a scale from 0 (all of the time) to 4 (never). Possible overall scores ranged from 0 to 4, with higher scores indicating a better quality of life according to the different symptomatic criteria.
Months 1, 3, 6, and 12
Gastrointestinal Symptom Rating Scale Scores Over Time
기간: Months 1, 3, 6, and 12
The impact of gastrointestinal (GI) symptoms on health-related quality of life was assessed using the Gastrointestinal Symptom Rating Scale Scores (GSRS). The GSRS a 15-item self-administered questionnaire that assesses the impact of gastrointestinal symptoms during the past week on a scale from 1 (no discomfort at all) to 7 (very severe discomfort). Possible overall scores range from 1 to 7, with lower scores indicating a better quality of life with respect to gastrointestinal symptoms.
Months 1, 3, 6, and 12

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Principal Investigator, University of Michigan

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

유용한 링크

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2008년 2월 1일

기본 완료 (실제)

2011년 2월 1일

연구 완료 (실제)

2011년 2월 1일

연구 등록 날짜

최초 제출

2007년 10월 11일

QC 기준을 충족하는 최초 제출

2007년 10월 12일

처음 게시됨 (추정)

2007년 10월 15일

연구 기록 업데이트

마지막 업데이트 게시됨 (추정)

2015년 12월 11일

QC 기준을 충족하는 마지막 업데이트 제출

2015년 11월 6일

마지막으로 확인됨

2015년 11월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다